Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.
A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy.
Department of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
J
J
Ervens
M
M
Ghannoum
B
B
Graf
S
S
Schwartz
D000935:Antifungal Agents / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D009570:Nitriles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D012233:Rhizopus / Q000235:genetics / Q000302:isolation & purification* / Q000502:physiology; D016879:Salvage Therapy; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole